Why the study?
Do renin-angiotensin system-inhibiting drugs reduce the incidence of newly diagnosed diabetes in high-risk patients?
Do renin-angiotensin system-inhibiting drugs reduce the incidence of newly diagnosed diabetes in high-risk patients?
While retrospective and secondary analyses suggest RAS inhibitors reduce new-onset diabetes, prospective trials with diabetes as the primary endpoint are needed to confirm this effect.
Secondary analyses suggest possible reduction in new-onset diabetes; leaves open confirmation in prospective primary-endpoint trials.
The prevalence of type 2 diabetes is increasing worldwide, and prevention of the disease is a key objective. Several clinical trials reported a consistent reduction in the incidence of newly diagnosed diabetes in high-risk patients treated with renin-angiotensin system-inhibiting drugs. In all those trials, however, diabetes reduction was either a post-hoc analysis result or a secondary endpoint. Therefore, we need the results of ongoing specific prospectively designed trials, with new-onset diabetes as the principal endpoint.
No takes yet. Share an insight, caveat, or question.
Zanolla et al. (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: